News

Congratulations to the recipients of the inaugural BC Cancer Rising Stars Awards!

The Rising Stars program was established to celebrate Dr. Connie Eaves’ Gairdner Wightman Award, her election to the Royal Society in the UK and her appointment to the Order of Canada. A pioneer in her field, Dr. Eaves has been a mentor to many young researchers at BC Cancer and a long-time advocate for equal opportunities in cancer research.

Each year, the Till and McCulloch Award celebrates the best of Canadian science in the stem cell and regenerative medicine field. This year, a special Till and McCulloch Lifetime Achievement Award will celebrate the outstanding contributions that Dr. Connie Eaves has made throughout her distinguished career. The Till and McCulloch Lifetime Achievement Award recognizes the career-spanning, pivotal contributions that Dr. Eaves has made to the field of stem cell research, as well as to the training of next generations of outstanding researchers.

Personalis’ Next Personal™ liquid biopsy assay will be deployed in study collaboration 
 

Ly Vu has been awarded the Michael Smith Health Research BC Scholar Award for the project titled, "Post-transcriptional regulation of hematopoietic stem cell function during normal and malignant hematopoiesis."

The Michael Smith Health Research BC Scholar Program supports early-career health researchers who are building leading-edge health research programs, training the next generation of scientists and expanding their potential to make significant contributions to their field.

BC Cancer researchers are playing a central role in a new international collaboration aimed at developing innovative treatments for osteosarcoma — a highly malignant bone cancer that commonly affects children and adolescents.

More than a dozen people with cancer who had exhausted all treatment options are alive and cancer-free today thanks to a pioneering Canadian clinical trial of a highly personalized kind of immunotherapy. The results, presented at the 2022 Cell Therapy Transplant Canada Conference, could open the door to a new era of made-in-Canada immunotherapies for cancer.